第1届
Network Pharmacology
-网路药理学讨论会-
有效的癌治疗药之创药和开发
2月19日～20日
网路药理学乃指研究人员能正确理解药物发生作用的机制之科学，已蔚为创药及新药开发领域的新领域。以解决临床试验后期阶段化合物/分子耗损的问题为目标，制药业界致力于自我检查，为加深对临床前阶段领导性分子的理解，采用多次元的新方法。药学研究人员相当早以前就已体认到违反有效的癌治疗药1个标的1种药剂想法的「复合药理」之活性的事实。本讨论会中能直接遇到参与癌治疗各种领域的专家，聆听其对复数标的的功效为新药开发打开一条道路的可能性等意见。运用由药理染色体组、标的识别、计算机的建模、分析开发、系统生物学等产生的网路药理学，活用可利用的信息，掌握对各种分子复数标的的效果。此外，网路药理学在赋予药剂地位和变更目的作业迅速化之点上亦有一定的作用。此讨论会中，从事创药和新药开发的制药业界和大学、政府机关的专家齐聚一堂，介绍网路药理学的技术、策略和方法等。请勿错过参加亦能接触到低分子化合物和高分子化合物开发专案的个案研究、有关网路药理学应用的专题讨论会之此机会。
Who should attend: Clinical pharmacologists, informatics specialists, systems biologists, pharmaceutical leaders, drug reposition experts, pre-clinical pharmacologists, ADME/tox specialists, lead validation experts, target identification experts, as well as researchers in oncology, inflammation, cardiovascular, neurology and anyone interested in new technologies & methods for better predicting efficacious drugs.
Topics will include, but are not limited to:
- Network pharmacology
- Mechanism of action
- Drug action
- Drug targeting
- Polypharmacology
- Pharmacogenomics
- In silico modeling
- Bioinformatics
- Cheminformatics
- Drug repositioning
- Drug repurposing
- Network biology
- Systems biology
- Computational biology
- Target identification
- Target validation
The deadline for submission is July 29, 2011.
All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
